This study was a multicenter, real-world observational study aimed at characterizing the genomic landscape of recurrence in patients with EGFR-sensitizing mutation-positive early-stage (clinical stage IB-IIIA) non-small cell lung cancer who received adjuvant osimertinib after surgery.
Informed consent signed;
Age ≥ 18 years;
Histologically confirmed diagnosis of non-squamous non-small cell lung cancer;
Patients with stage IB-IIIA (TNM 8#) NSCLC undergo confirmed radical R0 resection;
Patients with stage I-III NSCLC whose surgical resection cannot be confirmed;
Received adjuvant therapy other than that specified in the ADAURA study;
No NGS test report at recurrence;
History of other malignant tumors within 2 years;